13.03.2015 • NewsDede WillamsCatalysis & CatalystsEvonik

Evonik to Acquire Indian Specialty Catalyst Maker

To strengthen its global catalysts business and broaden its portfolio, German chemical producer Evonik has agreed to acquire 100% of India-based Monarch Catalyst.

The transaction is expected to close during the first half of this year, following all approvals. The purchase price is not being disclosed.

Evonik's business line Catalysts is a globally leading producer of specialty catalysts, custom catalysts and catalyst components for the life sciences, fine chemicals, industrial and petrochemical /polyolefin market segments.

With annual sales in the low double-digit million euro range, Monarch, whose portfolio includes global oils & fats hydrogenation catalysts, complements Evonik's leading positions in activated base metal catalysts and precious metal catalysts, the Essen-based group said.

Monarch Catalyst employs around 300 People.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.